Antibacterial Drug Use and Resistance in Psychiatric Hospitals: Scientific Perspectives on Cefodizime

Study Background and Research Question

The COVID-19 pandemic has posed unique challenges for healthcare institutions worldwide, with psychiatric hospitals facing particularly complex circumstances due to patient vulnerability and institutional environments. These facilities must manage both mental and physical health concerns, and their patients—often with impaired immunity and limited self-care—are at heightened risk for bacterial infections. The intensified use of antibacterial agents, especially broad-spectrum antibiotics, has raised concerns about the emergence and spread of resistant pathogens. However, little systematic data existed regarding antibacterial drug utilization and resistance dynamics in psychiatric hospital settings during epidemic periods. The recent study by Jiang et al. addressed this gap by retrospectively analyzing antibiotic use and bacterial resistance patterns in a large psychiatric hospital during the 2022 epidemic, focusing in particular on third-generation cephalosporins such as cefodizime.

Key Innovation from the Reference Study

The primary innovation of the reference study lies in its comprehensive, real-world assessment of antibacterial drug consumption and associated resistance profiles within a psychiatric hospital over an epidemic year. By leveraging both hospital information systems and national surveillance databases, the authors provided a nuanced view of antibiotic selection, usage intensity, and resistance trends specific to this unique institutional context. Notably, the study identified cefodizime as the most frequently used third-generation cephalosporin, positioning it as a key agent for empirical therapy and resistance monitoring in psychiatric settings.

Methods and Experimental Design Insights

Jiang et al. conducted a retrospective, data-driven investigation utilizing two primary sources: the hospital's internal information system and the National Antibacterial Drug Clinical Application Monitoring Network. Data for the year 2022 were extracted, encompassing the rate and intensity of antibacterial usage, frequency of combined drug regimens, cumulative defined daily doses (DDDs), cost proportions, and microbiological testing rates. Pathogen identification data and results of antimicrobial susceptibility testing were systematically collected for all positive samples. The analysis focused on both Gram-negative and Gram-positive bacteria, quantifying resistance to commonly used antibiotics, including cephalosporins (notably cefodizime), penicillins, and quinolones.

Protocol Parameters

• Antibiotic usage metrics: Calculated as use rate (% of patients), usage intensity (AUD), and cumulative DDDs per antibiotic class.
• Microbiological submission rate: Proportion of antibacterial therapy courses accompanied by microbiological testing (77.78% in this study).
• Resistance surveillance: Systematic reporting of susceptibility profiles for all clinically significant isolates over the study period.
• Antibiotic selection benchmarks: Usage compared to provincial and national data for context.

Core Findings and Why They Matter

The results revealed that during the 2022 epidemic, the psychiatric hospital demonstrated a relatively low antibiotic use rate (5.00%), modest usage intensity (AUD 3.07), and a combined medication rate of 11.11%. The cumulative DDDs reached 12,039.04, with antibiotic costs comprising just 3.95% of total drug costs—significantly lower than provincial and national norms. Importantly, the microbiological submission rate for cases receiving antibacterial therapy was 77.78%, outperforming broader benchmarks and supporting targeted therapy.

Third-generation cephalosporins, especially cefodizime, were the most frequently utilized antibiotic class, followed by penicillins and quinolones. Resistance surveillance demonstrated persistent challenges: Gram-negative organisms showed resistance to penicillins, cephalosporins, and quinolones (notably ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, and ciprofloxacin), while Gram-positive bacteria displayed resistance to penicillins, macrolides, and quinolones (notably penicillin, benzylpenicillin, erythromycin, levofloxacin, and ciprofloxacin). These patterns align with global concerns regarding antimicrobial resistance driven by broad-spectrum antibiotic use, even when stewardship practices are relatively strong.

The implications are significant: while the hospital's stewardship policies kept usage levels low, increased reliance on broad-spectrum agents like cefodizime still paralleled rising resistance rates. This underscores the complex interplay between necessary infection control during epidemics and the evolution of resistant strains, particularly in vulnerable psychiatric populations. The study recommends ongoing, granular resistance monitoring and periodic data-driven optimization of antimicrobial protocols to maintain clinical efficacy and public health value.

Comparison with Existing Internal Articles

The findings of Jiang et al. resonate with themes explored in several internal resources. For example, "Cefodizime: Unraveling Resistance Dynamics and Clinical Optimization" offers a multidimensional review of cefodizime's utility in resistance studies and rational antibiotic deployment, reinforcing the importance of surveillance-led stewardship highlighted by the reference study. Similarly, "Cefodizime: Mechanistic Insights and Next-Generation Applications" provides a mechanistic perspective on the drug's broad-spectrum action and its implications for resistance modeling—supporting the paper's focus on using third-generation cephalosporins as key tools in both clinical and research settings. Practical laboratory advice on protocol design and data interpretation can be found in "Cefodizime (SKU BA1050): Reliable Antibiotic for Sensitivity Research", which addresses workflow challenges that may parallel those encountered in real-world hospital surveillance.

Limitations and Transferability

While the study offers valuable insights, several limitations must be acknowledged. The retrospective design and single-institution scope may limit the generalizability of results to other psychiatric hospitals or broader healthcare settings. Additionally, the analysis did not stratify resistance data by clinical outcomes or specific infection types (e.g., respiratory versus urinary tract), which could inform more nuanced stewardship strategies. The findings, however, are broadly transferable to research and clinical teams engaged in antimicrobial activity studies, bacterial cell wall synthesis inhibitor evaluations, and the monitoring of immunomodulatory antibiotics in similar high-risk populations.

Research Support Resources

For researchers studying antimicrobial activity against respiratory and urinary tract infections or modeling resistance mechanisms in vitro, validated reagents and workflow protocols are essential. Cefodizime (SKU BA1050), available from APExBIO, offers a research-grade third-generation cephalosporin antibiotic with broad-spectrum activity suitable for cell-based and microbiological assays. Its stability against β-lactamases and robust pharmacological profile, as described in the product dossier, can help support experimental designs aligned with the stewardship and surveillance principles highlighted in the reference study. As always, such tools should be used in accordance with institutional protocols and not for clinical application.